Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy

被引：0
作者：
Lan-Lan Pang
Jia-Di Gan
Yi-Hua Huang
Jun Liao
Wei-Tao Zhuang
Wael-Abdullah-Sultan Ali
Shao-Dong Hong
Li Zhang
Wen-Feng Fang
机构：
[1] Sun Yat-Sen University Cancer Center,Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine
来源：
BMC Cancer | / 23卷
关键词：
Non-small cell lung cancer; Immunotherapy; Chemotherapy; Combination; Antiangiogenic agents; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
[21]   Disease Burden on PET Predicts Outcomes for Advanced NSCLC Patients Treated with First-Line Immunotherapy [J].
Andraos, Therese Y. ;
Halmos, Balazs ;
Cheng, Haiying ;
Huntzinger, Calvin ;
Shirvani, Shervin M. ;
Ohri, Nitin .
CLINICAL LUNG CANCER, 2022, 23 (04) :291-299
[22]   Ipilimumab-nivolumab as first-line treatment in metastatic NSCLC [J].
El-Ghazzi, Nathan ;
Lavaud, Pernelle .
BULLETIN DU CANCER, 2021, 108 (03) :231-233
[23]   Immunotherapy in the First-Line Treatment of Advanced Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis [J].
Guven, Deniz Can ;
Stephen, Bettzy ;
Sahin, Taha Koray ;
Cakir, Ibrahim Yahya ;
Aksoy, Sercan .
LARYNGOSCOPE, 2024, 134 (01) :7-17
[24]   Anlotinib Plus Docetaxel is Promising in Advanced NSCLC Progressing on First-Line Immunotherapy: A Pooled Analysis of Two Randomized Trials [J].
Pu, Xingxiang ;
Shou, Jiawei ;
Xiao, Zemin ;
Chen, Jun ;
Xiao, Maoliang ;
Guo, Qunyi ;
Ma, Zhongxia ;
Hong, Wei ;
Wang, Qianzhi ;
Wang, Yonghui ;
Li, Jia ;
Rao, Chuangzhou ;
Weng, Jie ;
Lu, Liqin ;
Wu, Lin ;
Fang, Yong .
ADVANCES IN THERAPY, 2025, 42 (07) :3249-3264
[25]   Optimizing first-line TKI treatment efficacy in PD-L1-positive EGFR-mutated NSCLC: the impact of antiangiogenic agents [J].
Jin, Xuanhong ;
Pan, Yang ;
Cheng, Cheng ;
Shen, Hangchen ;
Zhai, Chongya ;
Yin, Kailai ;
Zhu, Xinyu ;
Pan, Hongming ;
You, Liangkun .
FRONTIERS IN PHARMACOLOGY, 2024, 15
[26]   Treatment-Related Adverse Events in Patients with Advanced NSCLC Treated with First-Line Atezolizumab Chemoimmunotherapy [J].
Swarup, S. ;
Thein, K. ;
Sultan, A. ;
Jahan, N. ;
Quirch, M. ;
Meda, S. ;
Htut, T. ;
Adhikari, N. ;
Hlaing, P. ;
Dash, A. ;
Tun, A. ;
Rehman, S. ;
Hardwicke, F. ;
Tijani, L. .
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) :S390-S390
[27]   Clinical observation of gefitinib as a first-line therapy in sixty-eight patients with advanced NSCLC [J].
Gao, Zhiqiang ;
Han, Baohui ;
Wang, Huimin ;
Shi, Chunlei ;
Xiong, Liwen ;
Gu, Aiqin .
ONCOLOGY LETTERS, 2012, 3 (05) :1064-1068
[28]   Real World Efficacy of First-Line Immunotherapy plus /Chemotherapy in Advanced NSCLC Stratified by Serum Proteomics [J].
Akerley, W. ;
Halawani, H. ;
Schaefer, E. ;
Page, R. ;
Ghabach, B. ;
Evans, J. ;
Shunyakov, L. ;
Oubre, D. ;
Veatch, A. ;
Akulian, J. ;
Velcheti, V. ;
Pitcher, T. .
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) :S325-S325
[29]   Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial [J].
Ren, Shengxiang ;
Chen, Jianhua ;
Xu, Xingxiang ;
Jiang, Tao ;
Cheng, Ying ;
Chen, Gongyan ;
Pan, Yueyin ;
Fang, Yong ;
Wang, Qiming ;
Huang, Yunchao ;
Yao, Wenxiu ;
Wang, Rui ;
Li, Xingya ;
Zhang, Wei ;
Zhang, Yanjun ;
Hu, Sheng ;
Guo, Renhua ;
Shi, Jianhua ;
Wang, Zhiwu ;
Cao, Peiguo ;
Wang, Donglin ;
Fang, Jian ;
Luo, Hui ;
Geng, Yi ;
Xing, Chunyan ;
Lv, Dongqing ;
Zhang, Yiping ;
Yu, Junyan ;
Cang, Shundong ;
Yang, Zeyu ;
Shi, Wei ;
Zou, Jianjun ;
Zhou, Caicun .
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (04) :544-557
[30]   A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies [J].
Qu, Jialin ;
Wang, Li ;
Jiang, Man ;
Zhao, Deze ;
Wang, Yuyang ;
Zhang, Feng ;
Li, Jing ;
Zhang, Xiaochun .
CANCER MANAGEMENT AND RESEARCH, 2020, 12 :6493-6509
12345